Drug Profile
Research programme: anti-viral antisense therapies - Oncotelic Therapeutics
Latest Information Update: 30 Apr 2021
Price :
$50
*
At a glance
- Originator Mateon Therapeutics
- Developer Oncotelic Therapeutics
- Class Antisense elements; Antivirals; Oligonucleotides
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections; Viral infections
Highest Development Phases
- Research COVID 2019 infections; Viral infections